Christopher Richard Anzalone
Chief Executive Officer at Arrowhead Pharmaceuticals Inc.
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 3 years
- Director since
- 2023
3 years of board service in total across 1 board, counting each seat separately. Longest: Arrowhead Pharmaceuticals Inc., 3 years.
Arrowhead Pharmaceuticals Inc.
Director · Chief Executive Officer
Chief executive roles
Arrowhead Pharmaceuticals Inc.
· Chief Executive Officer
Dates unknown
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jan 2, 2026 | Arrowhead Pharmaceuticals Inc. | Open-market sale | −7,416 | $65.88 | $488,566 |
| Jan 2, 2026 | Arrowhead Pharmaceuticals Inc. | Open-market sale | −5,771 | $66.39 | $383,137 |
| Dec 29, 2025 | Arrowhead Pharmaceuticals Inc. | Option exercise | +35,181 | $6.15 | $216,363 |
| Dec 29, 2025 | Arrowhead Pharmaceuticals Inc. | Option exercise | +16,545 | $6.15 | $101,752 |
| Dec 29, 2025 | Arrowhead Pharmaceuticals Inc. | Open-market sale | −35,181 | $69.33 | $2,439,099 |
| Dec 29, 2025 | Arrowhead Pharmaceuticals Inc. | Open-market sale | −16,545 | $68.69 | $1,136,476 |
| Dec 22, 2025 | Arrowhead Pharmaceuticals Inc. | Open-market sale | −10,012 | $68.33 | $684,120 |
| Dec 22, 2025 | Arrowhead Pharmaceuticals Inc. | Open-market sale | −2,574 | $68.85 | $177,220 |
| Dec 19, 2025 | Arrowhead Pharmaceuticals Inc. | Open-market sale | −3,979 | $66.67 | $265,280 |
| Dec 19, 2025 | Arrowhead Pharmaceuticals Inc. | Open-market sale | −8,147 | $68.01 | $554,077 |
| Dec 19, 2025 | Arrowhead Pharmaceuticals Inc. | Open-market sale | −1,319 | $68.48 | $90,325 |
| Dec 17, 2025 | Arrowhead Pharmaceuticals Inc. | Open-market sale | −46,287 | $63.55 | $2,941,539 |
| Dec 17, 2025 | Arrowhead Pharmaceuticals Inc. | Open-market sale | −35,750 | $64.51 | $2,306,233 |
| Dec 17, 2025 | Arrowhead Pharmaceuticals Inc. | Open-market sale | −982 | $65.53 | $64,350 |
| Dec 17, 2025 | Arrowhead Pharmaceuticals Inc. | Open-market sale | −1,981 | $66.30 | $131,340 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.